{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-275470","form_type":"8-K","ticker":null,"cik":"0001834645","company_name":"Peak Bio, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.547102+00:00","generated_at":"2026-06-22T15:20:37.706398+00:00","sec_items":["1.01","3.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Peak Bio completes SPAC merger; receives Nasdaq delisting notice for low public float","bullets":["Completed business combination with Ignyte; common stock to trade as PKBO, warrants as PKBOW on Nasdaq from Nov 2, 2022.","Nasdaq notified company it fails to meet 1,000,000 unrestricted publicly held shares requirement; suspension set for Nov 10 unless hearing requested.","Entered new PIPE subscription agreements raising $3.025M from 302,500 shares and 281,325 warrants; also converted $1.75M in bridge loans into 176,579 shares and 164,218 warrants.","Waived closing conditions requiring $7.5M minimum cash and $20M total cash; Chardan withdrew as financial advisor and forfeited $550k fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-275470","json":"https://secwatch.observer/filing/0001193125-22-275470.json","markdown":"https://secwatch.observer/filing/0001193125-22-275470.md","text":"https://secwatch.observer/filing/0001193125-22-275470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/0001193125-22-275470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/d391470d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T15:20:37.706398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d122ce53f279378c1832a673022741a31128a9bc","claim":"Peak Bio, Inc. received a nasdaq deficiency notice notice regarding other (rules IM-5101-2, 5505(a)(2)).","evidence_excerpt":"November 1, 2022, Peak Bio, Inc. (the “ Company ”) received written notice (the “ Notice ”) from the Staff of the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Staff has determined that the Company has not complied with the requirements of IM-5101-2 because (i) the Company has not demonstrated that its common stock complies with the minimum 1,000,000 unrestricted publicly held shares requirement in Listing Rule 5505(a)(2) (the “ Unrestricted Publicly Held Shares Requirement ”) and (ii) the Company’s warrants do not qualify for in","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/0001193125-22-275470-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Rules","value":"IM-5101-2, 5505(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}